Menu

US Government Will Allow More Universities to Grow Pot

The US Drug Enforcement Agency continues to classify marijuana as a Schedule 1 drug, however, perpetuating challenges for researchers.

Aug 11, 2016
Kerry Grens

PIXABAY, CHEIFYCThe US Drug Enforcement Agency (DEA) has rebuffed a request by governors to downgrade marijuana from a Schedule 1 to a Schedule 2 drug, which would have eased restrictions on researchers who study the plant. However, the agency is announcing its plans to allow for additional facilities to grow pot.

“It will create a supply of research-grade marijuana that is diverse, but more importantly, it will be competitive and you will have growers motivated to meet the demand of researchers,” John Hudak, a senior fellow at the Brookings Institution, told The New York Times.

Up until now, marijuana growing was only permitted at the University of Mississippi. According to a policy statement on the Federal Register, “persons may become registered with DEA to grow marijuana not only to supply federally funded or other academic researchers, but also for strictly commercial endeavors funded by the private sector and aimed at drug product development. Likewise, under the new approach, should the state of scientific knowledge advance in the future such that a marijuana-derived drug is shown to be safe and effective for medical use, pharmaceutical firms will have a legal means of producing such drugs in the United States.”

Would-be growers will have to file applications with the DEA.

“This is a good day for science,” Kevin Sabet, president of Smart Approaches to Marijuana, a group that opposes legalization, told Reuters. “This shows that the federal government is flexible on legitimate research but is nowhere near wanting to legalize marijuana.”

 

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.